[{"address1": "201 Brookline Avenue", "address2": "Suite 901", "city": "Boston", "state": "MA", "zip": "02215", "country": "United States", "phone": "857 320 4900", "website": "https://www.tangotx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 140, "companyOfficers": [{"maxAge": 1, "name": "Dr. Barbara L. Weber M.D.", "age": 66, "title": "President, CEO & Director", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 1039811, "exercisedValue": 0, "unexercisedValue": 9991192}, {"maxAge": 1, "name": "Dr. Adam S. Crystal M.D., Ph.D.", "age": 46, "title": "President of Research & Development", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 977216, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alan  Ashworth FRS, Ph.D.", "age": 62, "title": "Founder & Member of Scientific Advisory Board", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Levi  Garraway M.D., Ph.D.", "age": 54, "title": "Founder", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William G. Kaelin Jr., M.D.", "age": 65, "title": "Founder & Member of Scientific Advisory Board", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Timothy K. Lu M.D., Ph.D.", "age": 42, "title": "Founder", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Antoni  Ribas M.D., Ph.D.", "age": 56, "title": "Founder & Member of Scientific Advisory Board", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy  Redfern", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Palmieri Ph.D.", "title": "Head of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jannik N. Andersen Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 4, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.85, "open": 2.83, "dayLow": 2.7, "dayHigh": 3.075, "regularMarketPreviousClose": 2.85, "regularMarketOpen": 2.83, "regularMarketDayLow": 2.7, "regularMarketDayHigh": 3.075, "beta": 0.879, "forwardPE": -2.1119616, "volume": 2795689, "regularMarketVolume": 2795689, "averageVolume": 1865926, "averageVolume10days": 1329120, "averageDailyVolume10Day": 1329120, "bid": 3.03, "ask": 3.1, "bidSize": 100, "askSize": 100, "marketCap": 328699072, "fiftyTwoWeekLow": 2.7, "fiftyTwoWeekHigh": 13.005, "priceToSalesTrailing12Months": 7.576679, "fiftyDayAverage": 4.8508, "twoHundredDayAverage": 7.7438, "currency": "USD", "enterpriseValue": 73046520, "profitMargins": -2.84432, "floatShares": 60550350, "sharesOutstanding": 107418000, "sharesShort": 7222311, "sharesShortPriorMonth": 9084727, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.0672, "heldPercentInsiders": 0.12841, "heldPercentInstitutions": 1.00708, "shortRatio": 2.31, "shortPercentOfFloat": 0.1238, "impliedSharesOutstanding": 116840000, "bookValue": 2.134, "priceToBook": 1.4339268, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -123395000, "trailingEps": -1.15, "forwardEps": -1.42, "enterpriseToRevenue": 1.684, "enterpriseToEbitda": -0.532, "52WeekChange": -0.70576924, "SandP52WeekChange": 0.2764505, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "TNGX", "underlyingSymbol": "TNGX", "shortName": "Tango Therapeutics, Inc.", "longName": "Tango Therapeutics, Inc.", "firstTradeDateEpochUtc": 1599139800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "90cada1d-9f83-3886-ad2a-ac647db270d6", "messageBoardId": "finmb_424111353", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.06, "targetHighPrice": 16.0, "targetLowPrice": 8.0, "targetMeanPrice": 11.5, "targetMedianPrice": 11.5, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 293278016, "totalCashPerShare": 2.73, "ebitda": -137202000, "totalDebt": 37626000, "quickRatio": 7.803, "currentRatio": 8.004, "totalRevenue": 43383000, "debtToEquity": 16.418, "revenuePerShare": 0.402, "returnOnAssets": -0.2237, "returnOnEquity": -0.48794997, "freeCashflow": -62539248, "operatingCashflow": -122321000, "revenueGrowth": 0.082, "grossMargins": -2.2575, "operatingMargins": -2.8326, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-15"}]